Saida Sh. Karshieva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Saida Sh. Karshieva has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
- Vadim Sergeevich Pokrovskii
N.N. Blokhin National Medical Research Center of Oncology, Kashirskoe Shosse 23, 115522 Moscow, Russia
3 shared publications - Dmitry V. Shtansky
National University of Science and Technology “MISIS” Moscow Russian Federation
2 shared publications - Ekaterina S. Chikanova
Dostoevsky State University
2 shared publications - Elena A. Demidova
N.N. Blokhin National Medical Research Center of Oncology
2 shared publications - Elizaveta S. Permyakova
National University of Science and Technology “MISIS
2 shared publications - Kristina Yu. Kotyakova
National University of Science and Technology “MISIS”, Leninsky prospect 4, Moscow 119049, Russia
2 shared publications
Latest Publications
- 1 January 2026
- Published by FSBSI Research Institute of Human Morphology in CLINICAL AND EXPERIMENTAL MORPHOLOGY
- Vol. 15 (4)
Cancer stem cell heterogeneity and spheroid structures in different tumor cell lines
Introduction. High mortality, tumor recurrence, and resistance to therapy remain major challenges in oncology and are largely attributed to the presence of a distinct population of tumor cells known as cancer stem cells. They are resistant to adverse conditions and capable of self-renewal daughter cell generation, differentiation, and epithelial–mesenchymal transition. It remains unclear whether tumors contain a single population of stem cells or multiple heterogeneous populations organized in a hierarchical manner. The purpose of our study was to analyze cancer stem cell heterogeneity by investigating marker expression and the association of these cells with spheroidal structures in several tumor cell lines: glioblastoma U-251 and U-87, cervical cancer SiHa and HeLa, vulvar squamous cell carcinoma A431, and lung adenocarcinoma A549. Materials and methods. Immunocytochemical analysis was performed using antibodies against ALDH1, CD133, and CD34 as cancer stem cell markers. Results. Hierarchies of heterogeneous cancer stem cells were presumably found in the studied tumor cell lines. ALDH1+ and CD34+ predominate in A549 lung adenocarcinoma; CD133 and ALDH1, in U-251 and U-87 glioblastoma cultures; and HeLa and SiHa, in cervical carcinomas. Vulvar squamous cell carcinoma A431 is characterized by the lowest number of cancer stem cells. Clusters of cancer stem cells were found in spheroidal structures, which may correspond to their niches identified in the tumor tissue. Conclusion. Understanding cancer stem cell biology may contribute to the development of new therapeutic approaches. Keywords: cancer stem cells, heterogeneity, hierarchy, plasticity, spheroid structures
- 1 January 2026
- Published by FSBSI Research Institute of Human Morphology in CLINICAL AND EXPERIMENTAL MORPHOLOGY
- Vol. 15 (4)
Cancer stem cell heterogeneity and spheroid structures in different tumor cell lines
Introduction. High mortality, tumor recurrence, and resistance to therapy remain major challenges in oncology and are largely attributed to the presence of a distinct population of tumor cells known as cancer stem cells. They are resistant to adverse conditions and capable of self-renewal daughter cell generation, differentiation, and epithelial–mesenchymal transition. It remains unclear whether tumors contain a single population of stem cells or multiple heterogeneous populations organized in a hierarchical manner. The purpose of our study was to analyze cancer stem cell heterogeneity by investigating marker expression and the association of these cells with spheroidal structures in several tumor cell lines: glioblastoma U-251 and U-87, cervical cancer SiHa and HeLa, vulvar squamous cell carcinoma A431, and lung adenocarcinoma A549. Materials and methods. Immunocytochemical analysis was performed using antibodies against ALDH1, CD133, and CD34 as cancer stem cell markers. Results. Hierarchies of heterogeneous cancer stem cells were presumably found in the studied tumor cell lines. ALDH1+ and CD34+ predominate in A549 lung adenocarcinoma; CD133 and ALDH1, in U-251 and U-87 glioblastoma cultures; and HeLa and SiHa, in cervical carcinomas. Vulvar squamous cell carcinoma A431 is characterized by the lowest number of cancer stem cells. Clusters of cancer stem cells were found in spheroidal structures, which may correspond to their niches identified in the tumor tissue. Conclusion. Understanding cancer stem cell biology may contribute to the development of new therapeutic approaches. Keywords: cancer stem cells, heterogeneity, hierarchy, plasticity, spheroid structures
- Open Access
- 7 September 2025
- Published by Elsevier in Next Materials
- Vol. 9
Investigation of the antibacterial properties of superabsorbent hemostatic dressings containing ZnO against wound pathogens
- 7 September 2025
- Published by Elsevier in Next Materials
- Vol. 9
Open AccessInvestigation of the antibacterial properties of superabsorbent hemostatic dressings containing ZnO against wound pathogens
- Open Access
- 15 July 2025
- Published by Publishing House ABV Press in Russian Journal of Biotherapy
- Vol. 24 (2) , 41-47
Preclinical characteristics of siRNA duplexes as targeted adjuvants in malignant growth
Background. Small or short double-stranded interfering RNAs (siRNAs, small interfering RNAs) 20–25 nucleotides long are known to be able to target block uncontrolled malignant proliferation. As target genes, apoptosis inhibitors are considered, including the cellular glycoprotein CD47 (cluster of differentiation 47), and genes of the replicative complex that regulate the cell cycle in the S phase. This determines the relevance of the study in tumor models of siRNAs aimed at these targets as adjuvants.Aim. To evaluate the antiproliferative effects of novel siRNAs as adjuvants for immune-/chemotherapy in human colorectal and renal cancer models.Materials and methods. SiRNA/antiCD47 and two-component siRNA antiMSM4/antiLIVIN were developed at the Research Centre for Medical Genetics and studied in lipid dispersion for intravenous (IV) administration. Preclinical models – subcutaneous xenographs of RTK-8 colon cancer and human kidney cancer Rpoch-1/CD47, Balb/c nude mice were obtained from the N.N. Blokhin National Medical Research Center of Oncology. In the adjuvant mode, siRNA/antiCD47 was studied in combination with activated human macrophages (AM), siRNA antiMSM4/antiLIVIN (1:1) – with cyclic-dependent cytostatic oxaliplatin (OXP). Administration regimens are justified earlier. Efficacy parameters and criteria (treatment/control (T/C) ≤42 %), tolerability of effects and statistical analysis at p 0.05 are standard for experimental cancer therapy. Laboratory manipulations are regulated by the current recommendations of the Ministry of Health of the Russia.Results. The siRNA/anti-CD47 + AM regimen was practically ineffective at Rpoch-1/CD47, T/C = 45 % (p 0.05). The antiMCM4/antiLIVIN + 24 h siRNA regimen on an OXP-insensitive RTK-8 showed a significant adjuvant effect against cytostatic, T/C = 33–21 % versus T/Cmin = 49 % (p ≤0.05). Both combinations were tolerable.Conclusion. Preclinical study showed the controversy of the assumption about the possibility of adjuvant use of siRNA/antiCD47 with AM and the promise of antiMSM4/antiLIVIN siRNA on low-sensitivity to cycle-dependent OXR in human colon cancer with the possibility of cell cycle synchronization.
- 15 July 2025
- Published by Publishing House ABV Press in Russian Journal of Biotherapy
- Vol. 24 (2) , 41-47
Open AccessPreclinical characteristics of siRNA duplexes as targeted adjuvants in malignant growth
Background. Small or short double-stranded interfering RNAs (siRNAs, small interfering RNAs) 20–25 nucleotides long are known to be able to target block uncontrolled malignant proliferation. As target genes, apoptosis inhibitors are considered, including the cellular glycoprotein CD47 (cluster of differentiation 47), and genes of the replicative complex that regulate the cell cycle in the S phase. This determines the relevance of the study in tumor models of siRNAs aimed at these targets as adjuvants.Aim. To evaluate the antiproliferative effects of novel siRNAs as adjuvants for immune-/chemotherapy in human colorectal and renal cancer models.Materials and methods. SiRNA/antiCD47 and two-component siRNA antiMSM4/antiLIVIN were developed at the Research Centre for Medical Genetics and studied in lipid dispersion for intravenous (IV) administration. Preclinical models – subcutaneous xenographs of RTK-8 colon cancer and human kidney cancer Rpoch-1/CD47, Balb/c nude mice were obtained from the N.N. Blokhin National Medical Research Center of Oncology. In the adjuvant mode, siRNA/antiCD47 was studied in combination with activated human macrophages (AM), siRNA antiMSM4/antiLIVIN (1:1) – with cyclic-dependent cytostatic oxaliplatin (OXP). Administration regimens are justified earlier. Efficacy parameters and criteria (treatment/control (T/C) ≤42 %), tolerability of effects and statistical analysis at p 0.05 are standard for experimental cancer therapy. Laboratory manipulations are regulated by the current recommendations of the Ministry of Health of the Russia.Results. The siRNA/anti-CD47 + AM regimen was practically ineffective at Rpoch-1/CD47, T/C = 45 % (p 0.05). The antiMCM4/antiLIVIN + 24 h siRNA regimen on an OXP-insensitive RTK-8 showed a significant adjuvant effect against cytostatic, T/C = 33–21 % versus T/Cmin = 49 % (p ≤0.05). Both combinations were tolerable.Conclusion. Preclinical study showed the controversy of the assumption about the possibility of adjuvant use of siRNA/antiCD47 with AM and the promise of antiMSM4/antiLIVIN siRNA on low-sensitivity to cycle-dependent OXR in human colon cancer with the possibility of cell cycle synchronization.
- Open Access
- 15 May 2025
- Published by Publishing House ABV Press in Advances in molecular oncology
- Vol. 12 (2) , 68-76
MelCher5k/BRAF+ subcutaneous human melanoma xenograft with CD20 expression
Introduction. Metastatic melanoma of the skin (mMC) is characterized by an extremely unfavorable prognosis of survival. Significant remission of mMK is associated with the use of vemurafenib, which blocks the proliferation of cells with a mutation in the BRAF gene. However, after its cancellation, relapse develops rapidly, determining the need for continued treatment. The search for another therapeutic target in the primary mMC led to a small subpopulation of stem-like CD20 antigen-expressing cells. Pilot clinical trials of CD20-blocking rituxibam did not yield the desired result, which we interpreted as a lack of control of CD20 expression in recurrent cells, which is available only in vivo in an adequate human model of recurrent mMK / BRAF+ with high CD20 expression.Aim. To create an in vivo model of recurrent human mMC / BRAF+ with control of the representation of a subpopulation of cells with CD20 expression.Materials and methods. Vemurafenib (Roche, Switzerland), human melanoma cell culture MelCher5k / BRAF+, male Balb / c nude immunodeficient mice weighing 20–23 g breeding and maintenance at the N. N. Blokhin National Medical Research Center of Oncology were used. Mice with a transplanted tumor (n = 12) were divided into 2 groups: without the drug (control) and with the drug (vemurafenib). A comparative assessment of the growth dynamics of tumor nodes in the groups was carried out according to the volume ratio using the standard T / C (treatment / control) criterion, expressed as a percentage. The dynamics of the expression of S100, CD20, and CD45 markers was evaluated by flow cytofluorometry before the start of vemurafenib administration and at the end of follow-up.Results. According to the data obtained, in mice with MelCher5k / BRAF+ treated with vemurafenib from days 7 to 21, tumor reduction was observed from day 10 with complete remission by day 20. Relapses with the development of a tumor node at the implantation site (renewed growth of melanoma cells) occurred on day 28 (a week after drug withdrawal), and then the tumor progressed rapidly over the course of 34–41 days. In mice treated with vemurafenib, the proportion of CD20+ cells in the new focus was 35 %, which was 1.82 times higher than the proportion of CD20+ cells in the tumor of mice not treated with this drug (19 %). At the same time, the cells of the newly emerged tumor expressed the melanoma marker S100+ and did not express CD45.Conclusion. Thus, in vivo, using the MelCher5k / BRAF+ model, it was shown that in a recurrent tumor node developing after the use of vemurafenib, the proportion of stem-like cells expressing CD20 significantly increases. These data suggest that it is advisable to use the model to evaluate the clinical prospects of CD20-targeted agents capable of prolonging remission after vemurafenib withdrawal in patients with recurrent melanoma.
- 15 May 2025
- Published by Publishing House ABV Press in Advances in molecular oncology
- Vol. 12 (2) , 68-76
Open AccessMelCher5k/BRAF+ subcutaneous human melanoma xenograft with CD20 expression
Introduction. Metastatic melanoma of the skin (mMC) is characterized by an extremely unfavorable prognosis of survival. Significant remission of mMK is associated with the use of vemurafenib, which blocks the proliferation of cells with a mutation in the BRAF gene. However, after its cancellation, relapse develops rapidly, determining the need for continued treatment. The search for another therapeutic target in the primary mMC led to a small subpopulation of stem-like CD20 antigen-expressing cells. Pilot clinical trials of CD20-blocking rituxibam did not yield the desired result, which we interpreted as a lack of control of CD20 expression in recurrent cells, which is available only in vivo in an adequate human model of recurrent mMK / BRAF+ with high CD20 expression.Aim. To create an in vivo model of recurrent human mMC / BRAF+ with control of the representation of a subpopulation of cells with CD20 expression.Materials and methods. Vemurafenib (Roche, Switzerland), human melanoma cell culture MelCher5k / BRAF+, male Balb / c nude immunodeficient mice weighing 20–23 g breeding and maintenance at the N. N. Blokhin National Medical Research Center of Oncology were used. Mice with a transplanted tumor (n = 12) were divided into 2 groups: without the drug (control) and with the drug (vemurafenib). A comparative assessment of the growth dynamics of tumor nodes in the groups was carried out according to the volume ratio using the standard T / C (treatment / control) criterion, expressed as a percentage. The dynamics of the expression of S100, CD20, and CD45 markers was evaluated by flow cytofluorometry before the start of vemurafenib administration and at the end of follow-up.Results. According to the data obtained, in mice with MelCher5k / BRAF+ treated with vemurafenib from days 7 to 21, tumor reduction was observed from day 10 with complete remission by day 20. Relapses with the development of a tumor node at the implantation site (renewed growth of melanoma cells) occurred on day 28 (a week after drug withdrawal), and then the tumor progressed rapidly over the course of 34–41 days. In mice treated with vemurafenib, the proportion of CD20+ cells in the new focus was 35 %, which was 1.82 times higher than the proportion of CD20+ cells in the tumor of mice not treated with this drug (19 %). At the same time, the cells of the newly emerged tumor expressed the melanoma marker S100+ and did not express CD45.Conclusion. Thus, in vivo, using the MelCher5k / BRAF+ model, it was shown that in a recurrent tumor node developing after the use of vemurafenib, the proportion of stem-like cells expressing CD20 significantly increases. These data suggest that it is advisable to use the model to evaluate the clinical prospects of CD20-targeted agents capable of prolonging remission after vemurafenib withdrawal in patients with recurrent melanoma.
- Open Access
- 21 December 2024
- Published by ECO-Vector LLC in Russian Journal of Oncology
- Vol. 29 (3) , 224-233
In vivo antitumor effects of bis-benzimidazole derivatives in mouse melanoma and lung cancer models
BACKGROUND: The development of new antitumor agents on the basis of benzimidazoles opens new opportunities for treatment of the malignant tumors, including those refractory to conventional therapies. The benzimidazole derivatives demonstrate wide spectrum of biological activities, specifically antineoplastic effects, and high-level cytotoxicity toward human’s tumor cell lines. The exploration of antineoplastic effects of new synthetic benzimidazole derivatives in in vivo models of tumor growth will help the development of the effective doses and cancer treatment regimens with the use of such compounds. AIM: To assess the antineoplastic effects of the benzimidazole derivatives — monomeric compound MB2Py(Ac) and dimeric compound DB2Py(3) — in the continuous cellular models of Lewis lung carcinoma (LLC) and melanoma B16 in mice. MATERIALS AND METHODS: In vivo assessment of antineoplastic effects was performed in the continuous mouse models of Lewis lung carcinoma (LLC) and B16 melanoma after a single intravenous injection of MB2Py(Ac) and DB2Py(3). Irinotecan was used as a comparator drug. Antitumor effects were measured via standard parameters, such as tumor growth inhibition (TGI%) and tumor growth rate (TGR). RESULTS: The study compounds DB2Py(3) and MB2Py(Ac) used in the study doses and regimen demonstrated mild antitumor effect in the model of murine solid tumors (TGI 50%). In melanoma B16 model, the maximum tumor growth inhibition was 15% and 38.5%, respectively, for MB2Py(Ac) and DB2Py(3). In the lung carcinoma model, the mild effect was observed, e.g. 8% for MB2Py(Ac) and 23.4% for DB2Py(3). The effect of the comparator drug, irinotecan, was more expressive, although short-term. In particular, TGI achieved 52.5% for melanoma B16 and 34.5% for Lewis lung carcinoma (LLC). In general, melanoma B16 was more sensitive to the effects of both bis-benzimidazoles and irinotecan, compared to the lung carcinoma LLC. CONCLUSION: This study shows that the dimeric compound DB2Py(3) was the most promising among three study substances in the models of melanoma and lung carcinoma in mice. Nevertheless, its high toxicity imposes the necessity of further optimization for the clinical use. The substance MB2Py(Ac) demonstrated lowest efficacy, although it may be also explored in the modified treatment regimens.
- 21 December 2024
- Published by ECO-Vector LLC in Russian Journal of Oncology
- Vol. 29 (3) , 224-233
Open AccessIn vivo antitumor effects of bis-benzimidazole derivatives in mouse melanoma and lung cancer models
BACKGROUND: The development of new antitumor agents on the basis of benzimidazoles opens new opportunities for treatment of the malignant tumors, including those refractory to conventional therapies. The benzimidazole derivatives demonstrate wide spectrum of biological activities, specifically antineoplastic effects, and high-level cytotoxicity toward human’s tumor cell lines. The exploration of antineoplastic effects of new synthetic benzimidazole derivatives in in vivo models of tumor growth will help the development of the effective doses and cancer treatment regimens with the use of such compounds. AIM: To assess the antineoplastic effects of the benzimidazole derivatives — monomeric compound MB2Py(Ac) and dimeric compound DB2Py(3) — in the continuous cellular models of Lewis lung carcinoma (LLC) and melanoma B16 in mice. MATERIALS AND METHODS: In vivo assessment of antineoplastic effects was performed in the continuous mouse models of Lewis lung carcinoma (LLC) and B16 melanoma after a single intravenous injection of MB2Py(Ac) and DB2Py(3). Irinotecan was used as a comparator drug. Antitumor effects were measured via standard parameters, such as tumor growth inhibition (TGI%) and tumor growth rate (TGR). RESULTS: The study compounds DB2Py(3) and MB2Py(Ac) used in the study doses and regimen demonstrated mild antitumor effect in the model of murine solid tumors (TGI 50%). In melanoma B16 model, the maximum tumor growth inhibition was 15% and 38.5%, respectively, for MB2Py(Ac) and DB2Py(3). In the lung carcinoma model, the mild effect was observed, e.g. 8% for MB2Py(Ac) and 23.4% for DB2Py(3). The effect of the comparator drug, irinotecan, was more expressive, although short-term. In particular, TGI achieved 52.5% for melanoma B16 and 34.5% for Lewis lung carcinoma (LLC). In general, melanoma B16 was more sensitive to the effects of both bis-benzimidazoles and irinotecan, compared to the lung carcinoma LLC. CONCLUSION: This study shows that the dimeric compound DB2Py(3) was the most promising among three study substances in the models of melanoma and lung carcinoma in mice. Nevertheless, its high toxicity imposes the necessity of further optimization for the clinical use. The substance MB2Py(Ac) demonstrated lowest efficacy, although it may be also explored in the modified treatment regimens.
- 21 December 2024
- Published by ECO-Vector LLC in Russian Journal of Oncology
- Vol. 29 (3) , 234-244
Comparative evaluation of antitumor effects of methionine-γ-lyase in in vitro 2D and 3D human tumor models
BACKGROUND: Promising antitumor drug screening results obtained from monolayer cultures are often poorly reproduced in the in vivo models. Using clinically relevant 3D in vitro human tumor models, such as spheroids, provides a more reliable framework for evaluating antitumor activity. This is particularly important when the drug’s mechanism of action targets cellular metabolism. AIM: To conduct a comparative study of the antitumor activity of methionine-γ-lyase (MGL) in 2D and 3D human tumor models. MATERIALS AND METHODS: Human fibroblast cell culture and tumor cell lines, e.g. MCF7 human breast cancer, HCT-116 colorectal cancer, PANC-1 human pancreatic cancer, Huh7 liver cancer, and LNCaP human prostate cancer were used to evaluate MGL cytotoxicity. Cultural plates with low-adhesive coating were used to produce the spheroids. Cell survival was assessed using the resazurin test. RESULTS: The spheroid model showed higher cell survival after 72-hour MGL exposure compared with the monolayer culture model in all tested cultures. Fibroblasts demonstrated the lowest sensitivity to MGL exposure in both 2D and 3D culture models, with IC50=2.2 and 9.1 IU/mL, respectively. The rapidly proliferating PANC-1 and HCT-116 cells showed the highest sensitivity to MGL in 2D and 3D models: IC50=0.23 and 1.5 IU/mL; IC50=0.83 and 1.43 IU/mL, respectively. CONCLUSION: The effect of MGL on cell survival in the spheroid systems is less pronounced than in monolayers. The viability of cells exposed to survival MGL in the spheroid culture system is independent of spheroid size or growth rate. Despite the maximum cytotoxic effect being observed in the fast-growing spheroid model of colon cancer HCT-116, and the lowest in the model of slowly dividing fibroblasts, this dependence was not so obvious for other cell types. Overall, the spheroid model has proven useful for testing the specific activity of enzyme-based antitumor drugs, as far as it overcomes the excessive intrinsic sensitivity observed in monolayer cancer models.
- 21 December 2024
- Published by ECO-Vector LLC in Russian Journal of Oncology
- Vol. 29 (3) , 234-244
Comparative evaluation of antitumor effects of methionine-γ-lyase in in vitro 2D and 3D human tumor models
BACKGROUND: Promising antitumor drug screening results obtained from monolayer cultures are often poorly reproduced in the in vivo models. Using clinically relevant 3D in vitro human tumor models, such as spheroids, provides a more reliable framework for evaluating antitumor activity. This is particularly important when the drug’s mechanism of action targets cellular metabolism. AIM: To conduct a comparative study of the antitumor activity of methionine-γ-lyase (MGL) in 2D and 3D human tumor models. MATERIALS AND METHODS: Human fibroblast cell culture and tumor cell lines, e.g. MCF7 human breast cancer, HCT-116 colorectal cancer, PANC-1 human pancreatic cancer, Huh7 liver cancer, and LNCaP human prostate cancer were used to evaluate MGL cytotoxicity. Cultural plates with low-adhesive coating were used to produce the spheroids. Cell survival was assessed using the resazurin test. RESULTS: The spheroid model showed higher cell survival after 72-hour MGL exposure compared with the monolayer culture model in all tested cultures. Fibroblasts demonstrated the lowest sensitivity to MGL exposure in both 2D and 3D culture models, with IC50=2.2 and 9.1 IU/mL, respectively. The rapidly proliferating PANC-1 and HCT-116 cells showed the highest sensitivity to MGL in 2D and 3D models: IC50=0.23 and 1.5 IU/mL; IC50=0.83 and 1.43 IU/mL, respectively. CONCLUSION: The effect of MGL on cell survival in the spheroid systems is less pronounced than in monolayers. The viability of cells exposed to survival MGL in the spheroid culture system is independent of spheroid size or growth rate. Despite the maximum cytotoxic effect being observed in the fast-growing spheroid model of colon cancer HCT-116, and the lowest in the model of slowly dividing fibroblasts, this dependence was not so obvious for other cell types. Overall, the spheroid model has proven useful for testing the specific activity of enzyme-based antitumor drugs, as far as it overcomes the excessive intrinsic sensitivity observed in monolayer cancer models.
- 25 March 2024
- Published by Federal Medical Biological Agency
- No. 2024(1)
Combined matrices and tissue-engineered constructs made of biopolymers in reconstructive surgery of ENT organs
Microtia is a combined congenital malformation with the prevalence of one case per 10,000–15,000 newborns, which accounts for 50% of all congenital malformations. Treatment of microtia is a challenging task. Numerous solutions have been proposed, however, none of these options guarantee good functional and aesthetic outcome. High hopes for solving the problem are placed on advances in reconstructive surgery. The study was aimed to determine the possibility of using advanced biocompatible endoprostheses manufactured using the tissue engineering technologies. Two closely related male 2-year-old minipigs of the Sus salvanius breed underwent implantation of bioengineered implants manufactured by combined 3D bioprinting with application of the collagen solution containing autologous cartilage tissue cells under the temporal fascia. The samples were collected 3 months later. Histological examination and immunohistochemistry showed that the implanted endoprosthesis initiated the development of regenerated connective tissue and its own vasculature in 100% of cases, thereby ensuring cell viability and integrity of biological structures; furthermore, no facts of the endoprosthesis rejection or resorption were reported. We have concluded that the developed implant manufacturing method is promising and can provide the basis for creation of domestic porous ear implants based on biocompatible polymeric materials, hydrogels, and autologous cellular material. It is necessary to further test the auricular implant using biological models.
- 25 March 2024
- Published by Federal Medical Biological Agency
- No. 2024(1)
Combined matrices and tissue-engineered constructs made of biopolymers in reconstructive surgery of ENT organs
Microtia is a combined congenital malformation with the prevalence of one case per 10,000–15,000 newborns, which accounts for 50% of all congenital malformations. Treatment of microtia is a challenging task. Numerous solutions have been proposed, however, none of these options guarantee good functional and aesthetic outcome. High hopes for solving the problem are placed on advances in reconstructive surgery. The study was aimed to determine the possibility of using advanced biocompatible endoprostheses manufactured using the tissue engineering technologies. Two closely related male 2-year-old minipigs of the Sus salvanius breed underwent implantation of bioengineered implants manufactured by combined 3D bioprinting with application of the collagen solution containing autologous cartilage tissue cells under the temporal fascia. The samples were collected 3 months later. Histological examination and immunohistochemistry showed that the implanted endoprosthesis initiated the development of regenerated connective tissue and its own vasculature in 100% of cases, thereby ensuring cell viability and integrity of biological structures; furthermore, no facts of the endoprosthesis rejection or resorption were reported. We have concluded that the developed implant manufacturing method is promising and can provide the basis for creation of domestic porous ear implants based on biocompatible polymeric materials, hydrogels, and autologous cellular material. It is necessary to further test the auricular implant using biological models.
- 20 December 2023
- Published by ECO-Vector LLC in Russian Journal of Oncology
- Vol. 28 (1) , 5-14
Cytotoxic and Anticancer Activity of Pharmacological Pairs of C115H Methionine–Gamma-lyase and S-Propyl-L-Cysteine Sulfoxide
BACKGROUND: One of the alternate ways to developing novel medication is to use pharmacological pairs: an enzyme and a non-toxic prodrug that, under certain conditions, releases cytotoxic substances within or on the surface of the cancer cells, allowing the drug to be delivered precisely to the cancer cells. AIM: To evaluate cytotoxic and anticancer effects of the pharmacological pair of C115H methionine-γ-lyase (C115H MGL), conjugated with daidzein (C115H MGL-Dz), and S-propyl-L-cysteine sulfoxide (propiin) against different kinds of solid tumors in vitro and in vivo. METHODS: MTT-test was performed to determine the cytotoxicity of C115H MGL-Dz in the presence of propiin in vitro against human embryonic kidney (HEK-293), human placenta, breast cancer (MCF7, SKBR3, and T47D), colon cancer (HT29 and COLO205), pancreatic cancer (MIA PaCa-2) and prostate cancer (DU145, and PC3) cells. The anticancer activity of the pharmacological pair "C115H MGL-Dz + propiin" against SKBR3, MIA PaCa-2, and HT29 in vivo was investigated using subcutaneous xenografts in BALB/c nude mice. RESULTS: In comparison to dipropylthiosulfinate generated in vitro using the pharmacological pairs "C115H MGL + propiin", targeted delivery of C115H MGL-Dz as a component of a pharmacological pair "C115H MGL-Dz + propiin" to generate dipropylthiosulfinate directly on the surface of cancer cells enhances cytotoxicity in all cancer cells. The study of the antitumor activity of the pharmacological pair "C115H MGL-Dz + propiin" in vivo revealed a suppression of tumor volume growth in xenografts SKBR3 (tumor growth inhibition, TGI=89%, p=0.004), MIA PaCa-2 (TGI=50%, p=0.011), and HT29 (TGI=52%, p=0.04) vs control. CONCLUSIONS: On several cancer cells, the cytotoxicity and anticancer activity of dipropylthiosulfinate produced by the pharmacological pair "C115H MGL-Dz + propiin" was observed. Our findings may stimulate more study into the role of pharmacological pairs as a novel strategy to cancer treatment.
- 20 December 2023
- Published by ECO-Vector LLC in Russian Journal of Oncology
- Vol. 28 (1) , 5-14
Cytotoxic and Anticancer Activity of Pharmacological Pairs of C115H Methionine–Gamma-lyase and S-Propyl-L-Cysteine Sulfoxide
BACKGROUND: One of the alternate ways to developing novel medication is to use pharmacological pairs: an enzyme and a non-toxic prodrug that, under certain conditions, releases cytotoxic substances within or on the surface of the cancer cells, allowing the drug to be delivered precisely to the cancer cells. AIM: To evaluate cytotoxic and anticancer effects of the pharmacological pair of C115H methionine-γ-lyase (C115H MGL), conjugated with daidzein (C115H MGL-Dz), and S-propyl-L-cysteine sulfoxide (propiin) against different kinds of solid tumors in vitro and in vivo. METHODS: MTT-test was performed to determine the cytotoxicity of C115H MGL-Dz in the presence of propiin in vitro against human embryonic kidney (HEK-293), human placenta, breast cancer (MCF7, SKBR3, and T47D), colon cancer (HT29 and COLO205), pancreatic cancer (MIA PaCa-2) and prostate cancer (DU145, and PC3) cells. The anticancer activity of the pharmacological pair "C115H MGL-Dz + propiin" against SKBR3, MIA PaCa-2, and HT29 in vivo was investigated using subcutaneous xenografts in BALB/c nude mice. RESULTS: In comparison to dipropylthiosulfinate generated in vitro using the pharmacological pairs "C115H MGL + propiin", targeted delivery of C115H MGL-Dz as a component of a pharmacological pair "C115H MGL-Dz + propiin" to generate dipropylthiosulfinate directly on the surface of cancer cells enhances cytotoxicity in all cancer cells. The study of the antitumor activity of the pharmacological pair "C115H MGL-Dz + propiin" in vivo revealed a suppression of tumor volume growth in xenografts SKBR3 (tumor growth inhibition, TGI=89%, p=0.004), MIA PaCa-2 (TGI=50%, p=0.011), and HT29 (TGI=52%, p=0.04) vs control. CONCLUSIONS: On several cancer cells, the cytotoxicity and anticancer activity of dipropylthiosulfinate produced by the pharmacological pair "C115H MGL-Dz + propiin" was observed. Our findings may stimulate more study into the role of pharmacological pairs as a novel strategy to cancer treatment.
- 20 December 2023
- Published by ECO-Vector LLC in Russian Journal of Oncology
- Vol. 28 (1) , 53-64
Antiproliferative activity of the novel CYP17A1 inhibitor alsevirone
BACKGROUND: Prostate cancer is the most frequently diagnosed type of cancer in men in developed countries. It is dependent upon androgens and could be effectively combated by androgen deprivation therapy. Reduction of androgen synthesis can be accomplished through the inhibition of the enzyme 17α-hydroxylase/17.20-lyase (CYP17A1), which catalyzes two sequential reactions in the production of androgens. Steroid derivatives modified with nitrogen-containing heterocycles attract attention as antineoplastic agents for prostate cancer treatment due to their inhibitory potential against CYP17A1. AIM: Evaluate cytotoxic activity and antitumor effects of the synthesized alsevirone in comparison with abiraterone. METHODS: Cytotoxicity was evaluated using MTT test. Anticancer effect was researched in vivo in prostate cancer xenograft models 22Rv1 and DU145 in Balb/c nude mice. Testosterone concentration was determined using an enzyme-linked immunosorbent assay in blood serum of BDF1 mice. RESULTS: Alsevirone demonstrated cytotoxic activity in prostate cancer cells: DU145 (23.8±1.2 µM vs 151.4±23.7 µM for abiraterone), 22Rv1 (35.9±5.6 µM vs 109.9±35.2 µM for abiraterone) and LNCaP (22.9±0.5 µM vs 28.8±1.6 µM for abiraterone). Testosterone concentration in blood serum of BDF1 mice reduced by 80% after 10-day treatment. Inhibition of the tumors’ growth in 22Rv1 xenograft model was statistically significant when using alsevirone in comparison with the control group: average tumor volume was 171.6±50.1 mm3 (р=0.022) vs 424.2±70.3 mm3 in control, with tumor growth inhibition index of 59%. CONCLUSIONS: Alsevirone has a higher cytotoxic potential against prostate cancer cells (DU145, LNCaP and 22Rv1) compared to abiraterone. Alsevirone demonstrated the ability to reduce the concentration of testosterone in the blood serum of BDF1 mice, and statistically significant antitumor activity in 22Rv1 xenograft models.
- 20 December 2023
- Published by ECO-Vector LLC in Russian Journal of Oncology
- Vol. 28 (1) , 53-64
Antiproliferative activity of the novel CYP17A1 inhibitor alsevirone
BACKGROUND: Prostate cancer is the most frequently diagnosed type of cancer in men in developed countries. It is dependent upon androgens and could be effectively combated by androgen deprivation therapy. Reduction of androgen synthesis can be accomplished through the inhibition of the enzyme 17α-hydroxylase/17.20-lyase (CYP17A1), which catalyzes two sequential reactions in the production of androgens. Steroid derivatives modified with nitrogen-containing heterocycles attract attention as antineoplastic agents for prostate cancer treatment due to their inhibitory potential against CYP17A1. AIM: Evaluate cytotoxic activity and antitumor effects of the synthesized alsevirone in comparison with abiraterone. METHODS: Cytotoxicity was evaluated using MTT test. Anticancer effect was researched in vivo in prostate cancer xenograft models 22Rv1 and DU145 in Balb/c nude mice. Testosterone concentration was determined using an enzyme-linked immunosorbent assay in blood serum of BDF1 mice. RESULTS: Alsevirone demonstrated cytotoxic activity in prostate cancer cells: DU145 (23.8±1.2 µM vs 151.4±23.7 µM for abiraterone), 22Rv1 (35.9±5.6 µM vs 109.9±35.2 µM for abiraterone) and LNCaP (22.9±0.5 µM vs 28.8±1.6 µM for abiraterone). Testosterone concentration in blood serum of BDF1 mice reduced by 80% after 10-day treatment. Inhibition of the tumors’ growth in 22Rv1 xenograft model was statistically significant when using alsevirone in comparison with the control group: average tumor volume was 171.6±50.1 mm3 (р=0.022) vs 424.2±70.3 mm3 in control, with tumor growth inhibition index of 59%. CONCLUSIONS: Alsevirone has a higher cytotoxic potential against prostate cancer cells (DU145, LNCaP and 22Rv1) compared to abiraterone. Alsevirone demonstrated the ability to reduce the concentration of testosterone in the blood serum of BDF1 mice, and statistically significant antitumor activity in 22Rv1 xenograft models.